SCHEMBL22130632

SCHEMBL22130632

N#Cc1ccc(S(=O)(=O)n2cc(-c3ccccc3)c3c2C=CC(=O)C3=O)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELAVL1 Q15717 7/20 0.77
CMA1 P23946 2/20 0.43
CTSG P08311 1/20 0.43
HTR6 P50406 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
PAX8 Q06710 1/20 0.39
PPME1 Q9Y570 1/20 0.38
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MAPT P10636 1/20 0.36
GBA1 P04062 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19737490 0.88 ELAVL1 (1.00) ELAVL1HTR6L3MBTL1MAPTCA12
SCHEMBL22130634 0.84 ELAVL1 (0.83) ELAVL1CMA1CTSGHTR6L3MBTL1
SCHEMBL21222486 0.84 ELAVL1 (1.00) ELAVL1CMA1CTSGHTR6L3MBTL1
SCHEMBL19737425 0.84 ELAVL1 (0.83) ELAVL1CMA1CTSGHTR6L3MBTL1
SCHEMBL22130693 0.83 ELAVL1 (0.81) ELAVL1HTR6L3MBTL1MAPTCA12
Dimethylamine SCHEMBL21222569 0.83 ELAVL1 (0.90) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130694 0.82 ELAVL1 (0.79) ELAVL1HTR6L3MBTL1MAPTCA12
SCHEMBL22130697 0.82 ELAVL1 (0.79) ELAVL1CMA1CTSGHTR6L3MBTL1
SCHEMBL22130695 0.81 ELAVL1 (0.76) ELAVL1HTR6L3MBTL1MAPTGBA1
SCHEMBL22130714 0.80 ELAVL1 (0.83) ELAVL1HTR6L3MBTL1MMP2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS ELAVL1 2765/4885CMA1 2572/4885CTSG 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.